American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 880-881 , June 2008

Kidney Transplantation in Children: The Preferred Option But Still No Cure

  • Jonathan C. Craig, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jonathan C. Craig, MD, Department of Public Health and Community Medicine, University of Sydney, NSW 2006, Sydney, Australia.

References 

  1. White CT, Schisler T, Lee E, Djurdjev O, Matsuda-Abedini M. CKD following kidney transplantation in children and adolescents. Am J Kidney Dis. 2008;51:996–1004
  2. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(suppl 1):S14–S266
  3. McDonald S, Craig JC. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:29–37
  4. Chacko B, Rajamanickam T, Neelakantan N, Tamilarasi V, John GT. Pediatric renal transplantation—a single center experience of 15 yr from India. Pediatr Transplant. 2007;11:844–849
  5. Magee JC, Bucuvalas JC, Farmer DG, Harmon WE, Hulbert-Shearon TE, Mendeloff EN. Pediatric transplantation. Am J Transplant. 2004;9(suppl 9):54–71
  6. Groothoff JW, Gruppen MP, Offringa M, et al. Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int. 2002;61:621–629
  7. Sarwal M, Pascual J. Immunosuppression minimization in pediatric transplantation. Am J Transplant. 2007;7:2227–2235
  8. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: a meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331:810–814
  9. Webster A, Lee VWS, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomised trials. Transplantation. 2006;81:1234–1248
  10. Phrommintikul A, Haas SJ, Elsik M, Klum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–388
  11. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: we were wrong, time to move on. Lancet. 2007;369:346–350
  12. Neal B, MacMahon S, Chapman N Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials (Blood Pressure Lowering Treatment Trialists' Collaboration). Lancet. 2000;356:1955–1964
  13. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews. 2007;(1):CD002003
  14. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147:840–853
  15. Strippoli GFM, Palmer S, Tong A, Elder G, Messa P, Craig JC. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis. 2006;47:715–726
  16. Rodrigo E, Fernandez-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol. 2006;17(suppl 3):S291–S295
  17. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am. 2007;36:873–890

PII: S0272-6386(08)00766-X

doi: 10.1053/j.ajkd.2008.04.009

American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 880-881 , June 2008

Article Tools